Genprex pairs gene therapy delivery tech with Keytruda in lung cancer trial

Genprex has begun testing a drug candidate based on its systemic gene therapy delivery platform in combination with Merck’s Keytruda. The phase 1/2 clinical trial marks the start of Genprex’s effort to determine whether a delivery system based on opposing electrical charges can help improve the efficacy of the checkpoint inhibitor in patients with late-stage non-small cell lung cancer (NSCLC).